Publications by authors named "C D de Kroon"
Cost-effectiveness of a nurse-led sexual rehabilitation intervention for women treated with radiotherapy for gynaecological cancer in a randomized trial.
Radiother Oncol
December 2024
Purpose: To compare the cost-effectiveness of a nurse-led sexual rehabilitation intervention with standard care in women treated with external beam radiotherapy, with or without brachytherapy, for gynaecological cancers.
Methods: Eligible women were randomly assigned to the intervention (n = 112) or standard care (n = 117). Primary endpoint was sexual functioning at 12-months post-radiotherapy, assessed by the Female Sexual Function Index (FSFI).
In patients with the rare adult-type granulosa cell tumors (aGCT), surgery is the primary treatment for both primary and recurrent disease. In cases of inoperable disease, systematic therapy is administered, but variable response rates and drug resistance complicate predicting the most effective therapy. Drug screen testing on patient-derived cell lines may offer a solution.
View Article and Find Full Text PDFFundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago of Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, we share our experiences in establishing the infrastructure, offer guidance for similar initiatives, and evaluate the AOCR patient cohort.
View Article and Find Full Text PDFArticle Synopsis
- The SHAPE trial showed that simple hysterectomy is just as effective as radical hysterectomy in preventing pelvic recurrence in low-risk early-stage cervical cancer, but offers better quality of life and sexual health.
- A cost-effectiveness analysis using a Markov model over 5 years found that simple hysterectomy costs less ($11,022) and provides more quality-adjusted life years (3.56 QALYs) compared to radical hysterectomy ($12,533 and 3.54 QALYs).
- The study concluded that simple hysterectomy is a better option overall due to being more cost-effective and yielding a higher quality of life post-surgery.
Article Synopsis
- Recent research on the HER2-targeted therapy trastuzumab-deruxtecan has led to a study examining HER2-low status in over 800 advanced endometrial cancer (EC) cases, which typically have a poor prognosis despite numerous treatment options.
- The study found that 17.2% of tumors were HER2-low, with higher frequencies in recurrent or metastatic EC (35.6%) and primary stage IV EC (29.9%), indicating HER2 status is present across various EC classifications without independent prognostic value.
- The findings suggest that a significant portion of high-risk and metastatic EC cases exhibit HER2 overexpression, emphasizing the importance of broad HER2 testing and potential treatment opportunities for diverse patient groups.